Clinical Trial Update: The CAMPUS Project: Cholinergic Augmentation of Cognitive Deficits in Schizophrenia [Phase 2]

View source ↗

Summary

The CAMPUS Project, a Phase 2 trial evaluating cholinergic augmentation of cognitive deficits in schizophrenia, has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizophrenia

Snippet

Sponsor: Birte Glenthoj | Conditions: Schizophrenia | Phase 2 | Status: TERMINATED